Genmab Stock Hits 52-Week High - Here's Why
Genmab shares gain as petosemtamab cuts head and neck cancer death risk by 50%, backing William Blair's $8 billion peak sales projections.
Share
Why It Matters
Genmab's new medicine showed it can cut cancer deaths in half. This success makes experts think the company could earn a lot of money from it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.